Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures
- PMID: 22041528
- PMCID: PMC3899457
- DOI: 10.2188/jea.je20100190
Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures
Abstract
China has one of the highest carrier prevalences of hepatitis B virus (HBV) in the world: nearly 10% of the general population. The disease burden of HBV infection and hepatocellular carcinoma (HCC) is also believed to be among the world's largest, and that of hepatitis C virus (HCV) infection is likely to be substantial as well. However, the epidemiology and measures to control HBV and HCV infection in China remain relatively unknown outside the country. We review the epidemiology of HBV and HCV infection, the disease burden of and risk factors for HCC, and current control measures against HBV and HCV infection in China. We also discuss the relevant literature and implications for future studies of hepatitis and HCC in China.
Figures
References
-
- Ministry of Health, China. National Plan for Prevention and Treatment against Hepatitis B for 2006–10.
-
- Qu ZY An epidemiological study on the distribution of HBsAg and anti-HBs in China . Chin J Microbiol Immunol. 1986;6:S20–40(in Chinese)
